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Background: Sagopilone (ZK 219477), a lipophylic and synthetic analog of epothilone B, that crosses the
blood–brain barrier has demonstrated preclinical activity in glioma models.
Patients and methods: Patients with first recurrence/progression of glioblastoma were eligible for this early phase II
and pharmacokinetic study exploring single-agent sagopilone (16 mg/m2 over 3 h every 21 days). Primary end point
was a composite of either tumor response or being alive and progression free at 6 months. Overall survival, toxicity and
safety and pharmacokinetics were secondary end points.
Results: Thirty-eight (evaluable 37) patients were included. Treatment was well tolerated, and neuropathy occurred in
46% patients [mild (grade 1) : 32%]. No objective responses were seen. The progression-free survival (PFS) rate at 6
months was 6.7% [95% confidence interval (CI) 1.3–18.7], the median PFS was just over 6 weeks, and the median
overall survival was 7.6 months (95% CI 5.3–12.3), with a 1-year survival rate of 31.6% (95% CI 17.7–46.4). Maximum
plasma concentrations were reached at the end of the 3-h infusion, with rapid declines within 30 min after termination.
Conclusions: No evidence of relevant clinical antitumor activity against recurrent glioblastoma could be detected.
Sagopilone was well tolerated, and moderate-to-severe peripheral neuropathy was observed in despite prolonged
administration.
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introduction
Despite recent progress with combined chemoradiotherapy,
glioblastoma—the most frequent and most malignant form of
primary brain tumors in adults—almost invariably recurs
[1, 2]. Treatment options for recurrent tumors are limited and
depend on the type of initial first-line therapy, the disease- or
progression-free interval, tumor size and location and the
patient’s general condition. Repeat surgery may be considered
for resectable tumors exerting a mass effect [3], while for
smaller tumors, re-irradiation is increasingly being considered.
Independent of these local treatments, additional systemic
therapy is indicated. Among agents with some established,
albeit limited, activity are temozolomide [4] and the
nitrosoureas lomustine and fotemustine [5–7] and carboplatin
[8]. However, single-agent response rates are usually below
10%, with up to 20%–30% of patients still free from
progression at 6 months. The rate of patients being alive and
progression free at 6 months (PFS6) has been established as
a reproducible surrogate end point [9].
New and active agents against recurrent glioblastoma are
urgently needed, and a number of classic cytotoxic and targeted
agents have been evaluated in this setting. Most recently,
bevacizumab has raised a lot of enthusiasm in the treatment of
o
ri
g
in
a
l
a
rt
ic
le
*Correspondence to: Dr R. Stupp, Department of Neurosurgery, University Hospital
CHUV, 46 rue du Bugnon, 1011 Lausanne, Switzerland. Tel: +41-21-314-0156;
Fax: +41-21-314-0737; E-mail: roger.stupp@chuv.ch
Present address: Department of Laboratory Medicine, Orebro University Hospital,
Orebro, Sweden.
Present address: Division of Oncology and Hematology, Chungnam National University
Hospital, Daejeon City, South Korea.
ª The Author 2011. Published by Oxford University Press on behalf of the European Society for Medical Oncology.
This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/by-nc/2.5), which permits
unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.
recurrent glioma with reported response rates of 25%–40%;
however, whether this translates into substantial prolongation
of survival remains to be demonstrated [10, 11].
Sagopilone (ZK 219477), fully synthetic analog of epothilone
B, inhibits microtubule depolarization, thus blocking the cell
cycle in the G2/M phase and inducing apoptosis [12]. This
mechanism of action is similar to that of taxanes (paclitaxel and
docetaxel). In contrast to taxanes, however, some epothilones
including sagopilone retain activity also against
multidrug-resistant tumors. ZK 219477 is not recognized by
cellular efflux mechanisms (ABC transporter) [13], and it
crosses the blood–brain barrier [14, 15].
In nude mice, sagopilone almost completely prevented the
growth of orthotopically implanted human glioma (U373, U87)
or breast cancer cell lines (brain metastases model) [14, 16].
The toxicity profile of ZK 219477, as emerging from phase I
studies, basically consists of peripheral sensory neuropathy,
mild nausea/vomiting, arthralgia, myalgia, diarrhea, fatigue,
alopecia as well as leucopenia and anemia. Peripheral
neuropathy, a toxicity common to tubulin-targeting agents, is
expected to be the most clinically relevant toxicity of ZK
219477 [17, 18].
Since ZK 219477 crosses the blood–brain barrier, the
occurrence of central nervous system toxicity may occur. Two
cases of ataxia of central nervous origin were observed at the
highest administered, and the maximum tolerated, dose, within
a phase I study, but not at doses of up to 16.4 mg/m2 [17].
Maximum concentrations of sagopilone are reached at the
end of the intravenous infusion, with rapid distribution into
tissues within minutes translating in a prolonged terminal
half-life of 2–3 days. The predominant route of sagopilone
elimination is via biliary/fecal excretion of metabolites
(Bayer Schering Pharma, data on file).
In a small exploratory trial, prolonged progression-free
survival (PFS) and overall survival was suggested in younger
patients with heavily pretreated glioblastoma or anaplastic
astrocytoma [19].
patients and methods
study design and patient selection
This concerns a one-stage early phase II and pharmacokinetic study
exploring single-agent activity of sagopilone in glioblastoma patients at first
progression. The study was developed, conducted and analyzed by the
European Organisation for Research and Treatment of Cancer (EORTC;
protocol #26061), in collaboration with Bayer Schering Pharma. Eligible
patients were adults (>18 years) with a histologically proven glioblastoma
according to the World Health Organization (WHO) classification. The
tumor must have recurred or progressed after primary therapy [either
combined chemoradiotherapy or one line of chemotherapy in case of
multifocal disease not amenable to radiotherapy (RT)]. Recurrence must be
evaluable and bidimensionally measurable on magnetic resonance imaging
(MRI), with a minimum of 2 cm for the largest diameter. No prior
chemotherapy for recurrent disease was allowed. Patients requiring
enzyme-inducing antiepileptic therapy were excluded or had to be switched
to alternative anticonvulsive therapy, with a washout period of >1 month.
Patients had to be on a stable or decreasing dose of corticosteroids for at
least 1 week before registration. Other eligibility criteria included a WHO
performance status of 0–2, an interval since the end of RT of at least 3
months, no prior high-dose RT >65 Gy (or target lesion outside the RT
field), normal hematological function (neutrophils ‡1.5 · 109 cells/l,
platelets ‡100 · 109 cells/l) and adequate hepatic [bilirubin <1.5 · upper
limit of the normal (ULN) range, alkaline phosphatase and transaminases
(ASAT–ALAT) <2.5 times ULN] and renal function (serum creatinine
<1.5 ULN). Surgery for recurrent disease was not allowed, unless residual
measurable disease was documented by postoperative MRI or computed
tomography within <72 h.
All patients gave written informed consent and the study was approved
by the local ethics committees of all participating institutions, and the
national regulatory authorities when applicable. The study was conducted
in accordance with the Declaration of Helsinki and Good Clinical Practice
Guidelines. The trial was registered at clinicaltrial.gov (NCT #00424060)
and at EudraCT (# 2006-001659-37).
end points and statistical analysis
The primary end point was a composite of either confirmed tumor response
according to the Macdonald criteria or being alive and progression free at 6
months [9, 20], an end point we also used in other studies for recurrent
disease [21, 22]. Secondary end points included overall survival, toxicity
and safety, as well as population pharmacokinetics in a subgroup of
patients. Adverse events were recorded according to the National Cancer
Institute—Common Toxicity Criteria version 3.0.
Statistical analysis was based on a one-stage Fleming design (P0, success
rate £8%; P1, success rate ‡23%; type I error = 10%; type II error = 10%),
‡5 successes to be observed to be considered active agent for further
investigation. PFS and overall survival was calculated from date of
registration until progression or death or censored at last follow-up
(updated May 2010) according to the Kaplan–Meier method.
treatment and evaluations
Sagopilone (ZK-EPO, ZK 219477) was administered as a 3-h intravenous
infusion every 3 weeks (one cycle). The tubing needed to be polyvinyl
chloride free in order to avoid adsorption of the agent. No specific
premedication (e.g. antihistamines or antiemetics) was recommended.
Sagopilone was provided by Bayer Schering Pharma, Berlin, Germany.
Baseline tumor imaging by MRI was to be carried out within 14 days
before treatment start and after every two cycles. Treatment was to be
continued until tumor progression or severe toxicity or patient refusal.
A clinical evaluation including physical and routine neurological
examination was carried out before each cycle of sagopilone, with
additional weekly clinic visits and complete blood count (CBC) during
cycle 1 only. From cycle 2 onwards, a CBC and blood chemistry were
carried out before each cycle of chemotherapy, a CBC also on day 15
(63 days).
The starting dose of sagopilone was 16 mg/m2, and dose reductions in
case of ‡ grade 3 toxicity to 12 and 9 mg/m2 were prespecified. Treatment
delays for up to 2 weeks due to toxicity were allowed.
pharmacokinetic analyses
Blood for pharmacokinetic analysis was drawn on cycle 1 before treatment
start, after 30 min, 5 min before the end of the 3-h infusion, 15 and 30 min
after the end of the infusion and then at hours 5, 6, 27 and 168. Samples
were collected into tubes containing Pefabloc SC to prevent ex vivo
degradation of sagopilone. Plasma concentrations of ZK 219477 were
determined by a validated liquid chromatography–mass spectrometry
method using 13C4-ZK 219477 as internal standard. The lower limit of
quantification was 0.1 ng/ml.
Pharmacokinetic parameters were calculated using a commercially
available software tool (EPS-Kinetica, Thermo Fisher Scientific,
Waltham, MA) without recourse to model assumptions.
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results
A total of 38 patients were recruited from December 2006 until
August 2007; however, 1 patient with grade II
thrombocytopenia at baseline never received treatment. Safety
is reported on the 37 treated patients including 1 patient who
did not meet the eligibility criteria (Figure 1). Tumor response
was calculated on the 36 eligible patients who started therapy,
and survival analyses were calculated on all 38 registered
patients (intent to treat). Patient characteristics are
summarized in Table 1. Median age was 57 years, and the great
majority of patients had a good performance status (WHO 0 or
1). Approximately half of the patients required steroids at
enrollment. A total of 100 cycles were administered to 37
patients, with a median of 2 cycles (range 1–6), 9 patients
(24%) received 4 or more cycles. On average, 96% of the
planned dose intensity was achieved.
safety and toxicity
Treatment was generally well tolerated, with grade 3 fatigue and
grade 3 neutropenia (inclusive 1 neutropenic infection)
occurring in three patients (8%) (for details, see Table 2).
Nevertheless, severe (grade 3 and grade 4) peripheral
neuropathy was reported in two patients (6%), with mild signs
of neuropathy recorded after cycle 2, and progression to severe
grade 3 or grade 4 neuropathy after cycle 3 and 4, respectively.
Grade 2 neuropathy was recorded in 3 patients, and grade 1 in
12 patients, thus almost half of the patients (46%) complained
of some, albeit mostly mild, neuropathy.
response and survival
No objective responses were seen. Stable disease as the best
response was reported in nine patients (25%). The PFS6 rate was
6.7% [95% confidence interval (CI) 1.3–18.7]; the median PFS
was just over 6 weeks, the moment of the first reevaluation
imaging (Figure 2). The median overall survival was 7.6 months
(95% CI 5.3–12.3), with three patients still alive at the time of the
analysis. The 1-year survival rate is 31.6% (95% CI 17.7–46.4).
sagopilone discontinuation and treatment after
progression
The great majority (31 patients, 81%) of patients discontinued
sagopilone due to progression. Three patients discontinued due
to toxicity (neuropathy, neutropenic infection and unrelated
muscle infection) and two patients refused continuation in the
Figure 1. Consolidated Standards of Reporting Trials (CONSORT) flow
chart.
Table 1. Patient characteristics
Characteristic Patients (N = 37a)
Age, median (range), years 57 (20–76)
Performance status, n (%)
0 and 1 31 (84)
2 6 (16)
Gender, n (%)
Male 28 (76)
Female 9 (24)
Prior chemotherapy, n (%)
No 1 (2)
TMZ/RT/TMZ 35 (92)
Other 1 (5)
Prior radiotherapy, n (%) 37 (100)
Concomitant medication at enrollment, n (%)
Steroids 20 (54)
Antiepileptic drugs (non-EIAED) 17 (46)
aThirty-eight patients enrolled [1 patient (44 years, performance status of
one, after prior TMZ/RT) not treated due to low baseline platelet count; 37
patients treated; 36 eligible].
RT, radiotherapy; TMZ, temozolomide; non-EIAED, non-enzyme-inducing
antiepileptic drugs.
Table 2. Adverse events according to Common Toxicity Criteria
Adverse event Worst toxicity, No. of patients (%)
Toxicity grade 1 2 3 4
Hematological toxicity
Leucopenia 12 (32) 4 (11) 2 (5) –
Neutropenia 6 (16) 1 (3) 3a (8) –
Thrombocytopenia 5 (14) 2 (5) – –
Anemia 10 (27) – – –
Neutropenic infection 1 (3)
Non-hematological toxicity
Fatigue 5 (14) 1 (3) 3 (8) –
Nausea/vomiting 3 (8) 2 (5) – –
Diarrhea 2 (5) 3 (8) – –
Neuropathy (peripheral) 14 (32) 3 (8) 1 (3) 1 (3)
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absence of severe toxicity. One patient died during protocol
therapy due to a non-treatment-related brain hemorrhage, and
coagulation parameters and platelet counts were within normal
limits. Treatment after progression was at the local
investigators’ discretion. At the time of the analysis, 22 patients
(58%) received further anticancer therapy, including 4 patients
who underwent salvage surgery and 3 patients who received
hyperthermia and chemotherapy combined.
pharmacokinetics
Limited pharmacokinetics was carried out on 14 patients;
a sample size of 10–15 patients was estimated sufficient for the
purpose of determining reliably plasma concentrations in
glioma patients and allowing for cross-study validation. One
subject was excluded from evaluation due to implausible
plasma concentrations at the end of infusion. Pharmacokinetic
parameters were calculated for 11 patients as the terminal
half-life/area under the concentration time curve and derived
parameters could not be calculated reliably in two patients.
During intravenous administration of sagopilone, maximal
plasma concentrations (Cmax) of 33.2 ng/ml were reached at the
end of the 3-h infusion (Figure 3). Sagopilone concentrations
rapidly declined to 30% of peak concentrations within 0.5 h
after end of the infusion. After the rapid distribution phase,
a long terminal disposition phase followed (mean terminal
half-life of 53 h). The main pharmacokinetic parameters are
summarized in Table 3.
discussion
Despite encouraging preclinical data, including almost
complete growth inhibition in an orthotopic glioma model,
a favorable pharmacokinetic profile of a lipophylic agent with
penetration across the blood–brain barrier and tolerable
toxicity allowing for delivery of adequate doses [12–14, 16], we
could not detect any evidence of relevant clinical antitumor
activity in recurrent glioblastoma. Most patients had progressed
at the time of first evaluation after only 6 weeks, contrary to
a prior report on 15 heavily pretreated and thus possibly very
selected patients with recurrent glioma of various histologies,
who had received a median of four cycles of sagopilone and
achieved disease stabilization in one third of the patients [19].
Compared with previous trials by our group with other agents
that were considered ineffective against glioma, the current rate
of stable disease at the first evaluation of <30% is lower than
expected despite favorable patient characteristics [21–24].
Overall, sagopilone was quite well tolerated, with neurotoxicity
being the most prominent side-effect despite prolongation of
the infusion time. Recently reported phase I trials identified
peripheral neuropathy as a dose limiting toxicity independent
of schedule of administration (weekly or 3 weekly) or infusion
duration (30 min versus 3 h) [17, 18]. The pharmacokinetic
profile established in our study is in accordance with other
trials where a 3-h infusion duration was used. As expected, peak
plasma concentrations were about fivefold lower with the 3-h
infusion duration compared with a 30-min infusion duration.
Figure 2. Overall and progression-free survival.
Annals of Oncology original article
Volume 22 | No. 9 | September 2011 doi:10.1093/annonc/mdq729 | 2147
Despite the absence of efficacy of single-agent sagopilone
against recurrent glioblastoma, the overall survival achieved in
the current trial is comparable to other reports. Although this
may be explained by patient selection and prognostic factors, it
also suggests that that second-line salvage therapy may well
have a role in the treatment of recurrent glioblastoma, despite
the lack of an accepted or established regimen. A recent phase I
trial investigated patupilone in conjunction with re-irradiation
in 10 patients with recurrent glioma [15]. A median survival of
25.5 months (95% CI 17–33.7) and a median PFS of 13.2
months were reported, indicating that this class of agent may be
particularly suited as radiation sensitizers in combination with
ionizing irradiation.
Since the inception of our trial, bevacizumab has been
identified as a potentially active agent for recurrent glioma. In
phase II trials, median survival times of 9 months have
repeatedly been shown, slightly longer than in our trial
[10, 11, 25, 26]. Except for one, none of our patients has
subsequently been treated with bevacizumab.
In conclusion, sagopilone has no relevant activity in
recurrent glioblastoma. The quest for novel and better agents
against malignant glioma continues.
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